Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Examining Opioid-Related Hospitalizations for Patients With Cancer

April 2, 2019
By Leah Lawrence
Article

Researchers looked at the trends and risk factors for opioid-related hospitalizations among patients with cancer.

Patients with cancer were rarely hospitalized for opioid-related reasons, according to a study published recently in JAMA Oncology. Although rates are increasing at a low rate over time, most of the hospitalizations are associated with non-heroin opioid poisoning, the study showed.

“In light of the wider opioid epidemic, oncologists and palliative care clinicians frequently balance providing patients with legitimate access to opioids while protecting them and the general public from the risks associated with prescribing these medications,” wrote Isaac S. Chua, MD, of Dana-Farber Cancer Institute, and colleagues in a research letter.

Chua and colleagues looked at the trends and risk factors for opioid-related hospitalizations among patients with cancer between 2006 and 2014 using data from the US National Inpatient Sample (NIS) of the Healthcare Cost and Utilization Project (HCUP). The primary outcome was opioid-related hospitalizations among adults age 18 or older.

Of the more than 25 million hospitalizations for patients with cancer, only 0.06% were related to opioids. From 2006 to 2014, the average number of opioid-related hospitalizations increased to 78.9 admissions per year (P = .01).

The majority of hospitalizations were non-heroin related (88.0%). The researchers identified several factors associated with opioid-related hospitalizations for patients with cancer, such as drug abuse (odds ratio [OR], 7.92; 95% CI, 6.95–9.02), depression (OR, 2.34; 95% CI, 2.13–2.58), psychotic disorder (OR, 4.13; 95% CI, 3.66–4.65), white race, younger age, and year of hospitalization.

“Prior to prescribing opioids for cancer-related pain, routinely screening patients using standardized tools based on these associated factors (eg, Opioid Risk Tool) may identify those patients with the greatest risk of an opioid-related hospitalization,” the researchers wrote. “Additional research on opioid risk screening and management for patients with combined cancer and substance use disorders is needed.”

Jon Mark Hirshon, MD, PhD, MPH, professor in the department of emergency medicine at the University of Maryland School of Science, told Cancer Network that these types of studies are important because “the issue of opioid misuse and abuse remains a significant and troubling societal problem causing widespread morbidity and mortality.”

“As a practicing emergency physician in inner-city Baltimore, I see this problem multiple times every shift. However, as noted within the article, the impact of this problem among patients with cancer is quite rare (0.06% of admissions) and has a very low rate of increase,” Hirshon said. “There are some weaknesses to the research, as it may underestimate the rate of the problem because it is based solely upon the primary diagnosis field and may have missed the diagnosis if placed in a secondary field. However, in the end, the article does not significantly impact clinical practice of emergency medicine and the need to remain vigilant both to the pain treatment needs of patients with cancer, as well as the continuing scourge of opioid misuse and abuse regardless of the patient population.”

Recent Videos
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practice in the breast cancer field.
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Related Content
Advertisement

At a median time to response of 1 month, isatuximab elicited a median duration of response of 10.3 months in patients with multiple myeloma.

Isatuximab Shows Efficacy, Acceptable Safety Across Multiple Myeloma Trials

Roman Fabbricatore
May 30th 2025
Article

At a median time to response of 1 month, isatuximab elicited a median duration of response of 10.3 months in patients with multiple myeloma.


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


Rhenium Obisbemeda Improves Survival in Recurrent Glioblastoma

Rhenium Obisbemeda Improves Survival in Recurrent Glioblastoma

Ariana Pelosci
May 30th 2025
Article

Andrew Brenner, MD, PhD, discussed rhenium obisbemeda and results from the ReSPECT-GBM trial for patients with glioblastoma.


Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.

Leveraging Artificial Intelligence to Bolster Equitable Cancer Care

Viviana Cortiana, MS4;Yan Leyfman, MD
May 19th 2025
Podcast

Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.


Combination therapies with teclistamab exhibited a superior overall response rate vs teclistamab monotherapy in relapsed/refractory multiple myeloma.

Teclistamab Shows Sustained Efficacy in R/R Multiple Myeloma

Roman Fabbricatore
May 30th 2025
Article

Combination therapies with teclistamab exhibited a superior overall response rate vs teclistamab monotherapy in relapsed/refractory multiple myeloma.


Ivonescimab plus chemotherapy reduced the risk of disease progression or death by 48% vs chemotherapy alone in patients with EGFR-mutant NSCLC.

Ivonescimab Combo Shows Meaningful PFS Improvement in EGFR-Mutant NSCLC

Roman Fabbricatore
May 30th 2025
Article

Ivonescimab plus chemotherapy reduced the risk of disease progression or death by 48% vs chemotherapy alone in patients with EGFR-mutant NSCLC.

Related Content
Advertisement

At a median time to response of 1 month, isatuximab elicited a median duration of response of 10.3 months in patients with multiple myeloma.

Isatuximab Shows Efficacy, Acceptable Safety Across Multiple Myeloma Trials

Roman Fabbricatore
May 30th 2025
Article

At a median time to response of 1 month, isatuximab elicited a median duration of response of 10.3 months in patients with multiple myeloma.


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


Rhenium Obisbemeda Improves Survival in Recurrent Glioblastoma

Rhenium Obisbemeda Improves Survival in Recurrent Glioblastoma

Ariana Pelosci
May 30th 2025
Article

Andrew Brenner, MD, PhD, discussed rhenium obisbemeda and results from the ReSPECT-GBM trial for patients with glioblastoma.


Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.

Leveraging Artificial Intelligence to Bolster Equitable Cancer Care

Viviana Cortiana, MS4;Yan Leyfman, MD
May 19th 2025
Podcast

Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.


Combination therapies with teclistamab exhibited a superior overall response rate vs teclistamab monotherapy in relapsed/refractory multiple myeloma.

Teclistamab Shows Sustained Efficacy in R/R Multiple Myeloma

Roman Fabbricatore
May 30th 2025
Article

Combination therapies with teclistamab exhibited a superior overall response rate vs teclistamab monotherapy in relapsed/refractory multiple myeloma.


Ivonescimab plus chemotherapy reduced the risk of disease progression or death by 48% vs chemotherapy alone in patients with EGFR-mutant NSCLC.

Ivonescimab Combo Shows Meaningful PFS Improvement in EGFR-Mutant NSCLC

Roman Fabbricatore
May 30th 2025
Article

Ivonescimab plus chemotherapy reduced the risk of disease progression or death by 48% vs chemotherapy alone in patients with EGFR-mutant NSCLC.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.